Company profile

IASO Biotherapeutics

Privately held: no public share price (Nanjing-based CAR-T cell-therapy biotech (CT103A/equecabtagene autoleucel), founded 2017. WebSearch confirmed it is a Series C+ private company with no independent public listing; an initial assumption of an HKEX listing (ticker 2126) was checked and found wrong -- 2126.HK actually belongs to the unrelated JW (Cayman) Therapeutics. Left private rather than guessed public. Sources: Tracxn, CBInsights, tradingview/cnbc/bloomberg quote pages for 2126.HK confirming the mismatch. Sources: https://clinicaltrials.gov/study/NCT05066646 Entity resolved by asset-pipeline-v2.)